Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Erica Stringer-Reasor, Rebecca Shatsky, Jo Chien, Anne M. Wallace et autres
us, nl, pt, ch (code pays fourni par la source)